Preparation method for oral protein immune carrier

A protein vaccine and carrier technology, applied in the field of medicine, can solve the problems of inability to achieve prevention or treatment, protein vaccine inactivation, etc., and achieve the effect of protection stability, surface pores and stable structure

Inactive Publication Date: 2017-05-31
CHINA PHARM UNIV
View PDF5 Cites 11 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0009] The present invention aims at protein vaccines being inactivated in the gastrointestinal tract due to the influence of various enzymes and environmental pH values ​​after oral administration, thus failing to achieve the effect of prevention or treatment. In addition, intramuscular or subcutaneous injection of vaccines can only induce The systemic immunity of the body can not induce the body to produce mucosal immunity and other problems. A carrier for oral protein vaccine is designed, and the carrier particles containing the protein antigen are transported to the macrophage through the transfer function of the carrier by the mucosal follicle-associated cells. Antigen-presenting cells such as cells and dendritic cells take it up, reprocess and present it to B and T cells, thereby inducing the body's immune response

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Preparation method for oral protein immune carrier
  • Preparation method for oral protein immune carrier
  • Preparation method for oral protein immune carrier

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0033] Preparation of mesoporous silica support:

[0034] (1) Accurately weigh 500mg of cetyltrimethylammonium bromide (CTAB), dissolve it in 70ml of deionized water, then add 0.8ml of ammonia solution, 20ml of absolute ethanol, and 20ml of ether, and stir vigorously at room temperature for 30 minutes After the solution became clear, 2.5 ml of tetraethylorthosilicate was quickly added dropwise thereto, and vigorously stirred for 4 hours to obtain a white solid precipitate.

[0035] (2) Suction filter the obtained white solid precipitate, wash the precipitate several times with ethanol and deionized water, and then dry it in a 60-degree oven for 24 hours.

[0036] (3) Accurately weigh 0.5 g of the dried solid powder, put it in 100 ml of ammonium nitrate / 95% ethanol with a concentration of 6 g / L, stir and reflux at 60 degrees for 5 hours, filter with suction, wash the precipitate, and dry in an oven , to obtain mesoporous silica.

Embodiment 2

[0038] Preparation of Mesoporous Silica Drug-loaded Particles:

[0039] (1) Accurately weigh 500mg of bovine serum albumin (BSA), put it in a 250mL volumetric flask, and dilute to the mark with phosphate buffer solution with a pH of 7.4 to obtain a BSA solution with a concentration of 2mg / mL as a stock solution.

[0040] (2) Accurately weigh 60 mg of mesoporous silica, add 30 ml of stock solution, stir at 4°C for 24 hours, centrifuge the solution, freeze-dry the precipitate, and obtain a freeze-dried powder of BSA loaded on mesoporous silica.

Embodiment 3

[0042] Preparation of chitosan mesoporous silica drug-loaded particles:

[0043] (1) Accurately measure 1 mL of acetic acid with a mass fraction of ≥99% in a 100 mL volumetric flask, and dilute to obtain a 1% acetic acid solution.

[0044] (2) Accurately weigh 50mg of chitosan, dissolve it in 10mL of 1% acetic acid solution, after it is completely dissolved, adjust its pH to about 5.5 with 2M sodium hydroxide solution, add deionized water to 25mL, and obtain the concentration 2mg / mL chitosan solution.

[0045](3) Accurately weigh 10 mg of mesoporous silica drug-loaded freeze-dried powder, add 1 mL of chitosan solution with a concentration of 2 mg / mL, stir at 4 degrees for 10 h, centrifuge the solution, and freeze-dry the precipitate to obtain chitosan Encapsulation of mesoporous silica drug-loaded particles.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
concentrationaaaaaaaaaa
Login to view more

Abstract

The invention relates to a preparation method for an oral protein immune carrier, and belongs to the field of medicines. A single template agent is utilized at a room temperature, a mesoporous silica material is synthesized by adopting a sol-gel method. Mesoporous silica particles loaded with a model drug are prepared by adopting bovine serum albumin (BSA) as the model drug and mesoporous silica as a carrier; and the drug loading capacity is 20-21%. Chitosan (CS) is adsorbed on the surface of the mesoporous silica through the electrostatic interaction, so that the biological adhesiveness of the carrier is improved, and the medicine can be effectively prevented from being damaged by a gastrointestinal tract environment. In addition, positively charged chitosan mesoporous silica drug-loaded composite particles are more easily ingested by cells to induce body immunoreaction.

Description

technical field [0001] The invention relates to a preparation method for oral protein immune carrier, which belongs to the field of medicine. Background technique [0002] As an effective defense weapon against diseases, vaccines play an important role in resisting infectious diseases. Many infectious diseases are caused by microbial pathogens invading the respiratory tract, gastrointestinal tract, and genitourinary tract, and the IgA secreted by the mucosal immune system can effectively prevent the invasion of microbial pathogens. After oral administration, IgA secreted by the gut-associated lymphoid tissue (GALT) can be transferred to distant mucosal sites such as the respiratory tract, urogenital tract, etc., thereby resisting the invasion of viral and microbial pathogens. However, most vaccines currently on the market are administered by subcutaneous injection or intramuscular injection, which can only induce systemic immunity and cannot trigger the mucosal immune syste...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K9/51A61K47/36A61K47/04
CPCA61K9/5161A61K47/02A61K2039/542
Inventor 王柏吴稀
Owner CHINA PHARM UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap